澳大利亚治疗用品管理局(TGA)已首次批准Wegovy口服片剂用于体重管理,使其成为该国首个获批的GLP-1类口服减重制剂 1。该药物含有司美格鲁肽成分,由制造商诺和诺德(Novo Nordisk)生产,获批强度包括1.5mg、4mg、9mg和25mg四种规格 1。这款片剂的推出旨在为不愿或不能接受注射治疗的患者提供替代方案 1。诺和诺德目标是在年底前让该药在澳大利亚上市 1。
在疗效方面,临床试验数据显示,服用该口服片剂64至68周可实现约14%的体重减轻,与每周注射版约15%的减重效果相似 1。然而,服用方式存在特定限制:患者需每日空腹服药,且在服药后须等待30分钟方可进食或饮水 1。安全性方面,约80%的使用者会出现常见副作用,主要包括恶心、呕吐和腹泻等胃肠道反应 1。此外,若停药后生活方式未发生改变,患者在一年内可能会反弹约三分之二的减重效果 1。
目前,Wegovy口服片剂尚未被列入澳大利亚药物福利计划(PBS),这意味着患者需要全额自费购买 1。参考现有注射剂每月约250至450澳元的费用,预计片剂的价格将处于相近水平 1。
The Therapeutic Goods Administration (TGA) has approved the oral tablet version of Wegovy for weight management, marking the first time a GLP-1 receptor agonist medication in pill form has been authorized in Australia 1. Manufactured by Novo Nordisk, the drug contains semaglutide and is available in four strengths: 1.5 mg, 4 mg, 9 mg, and 25 mg 1. This approval offers an alternative for patients who prefer not to use injectable treatments or are unable to do so 1.
Clinical trials indicate that the oral formulation achieves approximately 14% body weight reduction over a period of 64 to 68 weeks, which is comparable to the roughly 15% reduction seen with weekly injections 1. To ensure efficacy, patients must take the pill daily on an empty stomach and wait at least 30 minutes before eating or drinking anything other than water 1. Side effects such as nausea, vomiting, and diarrhea affect about 80% of users 1.
Novo Nordisk aims to launch the product in Australia by the end of this year 1. However, the medication is not currently included in the Pharmaceutical Benefits Scheme (PBS), meaning patients will need to pay the full cost out-of-pocket 1. The expected price is similar to the injectable version, which costs between A$250 and A$450 per month 1. It is important to note that if lifestyle changes are not maintained after stopping treatment, patients may regain approximately two-thirds of their lost weight within one year 1.
评论
还没有评论,欢迎留下第一条。